The purpose of this study is to evaluate the safety and efficacy of once daily oral inhalation dose of MK-5475 380 µg in participants 40 to 80 years (inclusive) with Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD). The primary hypothesis of the study is MK-5475, a soluble Guanylate Cyclase (sGC) stimulator is superior to placebo in increasing 6 Minute Walking Distance (6MWD) from baseline at Week 24.
1 Primary · 7 Secondary · Reporting Duration: Up to Week 104
120 Total Participants · 2 Treatment Groups
Primary Treatment: MK-5475 · Has Placebo Group · Phase 2
Age 40 - 80 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: